Il s'agit d'un magasin de démonstration. Aucune commande ne sera honorée.
Anticorps primaires
Filtrer par
-
Sabatolimab (anti-TIM-3), Antibody of TIM3 (CD366)Associated targets: HAVCR2Short Overview: Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG4SP; CHO; ELISA, FACS, Functional assay, Animal Model; UnconjugatedReactive species: Cynomolgus monkey, Human Isotype: Human IgG4SPEspèces hôtes: Human Conjugaison: UnconjugatedCas Number: 2252262-24-9Synonymes: HAVcr-2 | T-cell immunoglobulin and mucin domain-containing protein 3 | T-cell immunoglobulin mucin receptor 3 | T-ce...
-
Cobolimab (anti-TIM-3), INHIBITOR of Hepatitis A virus cellular receptor 2 inhibitorAssociated targets: HAVCR2Short Overview: Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG4SP; CHO; ELISA, FACS, Functional assay, Animal Model; UnconjugatedReactive species: Cynomolgus monkey, Human Isotype: Human IgG4SPEspèces hôtes: Human Conjugaison: UnconjugatedCas Number: 2022215-65-0SMILES: [Cobolimab]Synonymes: CD366 antibody | FLJ14428 antibody | HAVcr-2 antibody | Havcr2 antibody | HAVR2_HUMAN antibody | Hepatitis A virus ce...
-
Surzebiclimab (anti-TIM-3)Associated targets: HAVCR2Short Overview: Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; UnconjugatedReactive species: Human Isotype: Human IgG1Espèces hôtes: Human Conjugaison: UnconjugatedCas Number: 2342597-90-2Synonymes: CD366 antibody | FLJ14428 antibody | HAVcr-2 antibody | Havcr2 antibody | HAVR2_HUMAN antibody | Hepatitis A virus ce...
-
DS-6016A (anti-ACVR1)Associated targets: ACVR1Short Overview: Purity≥95% (SDS-PAGE&SEC-HPLC); Endotoxin Level<1.0 EU/mg; Human IgG1; CHO; ELISA, Flow Cytometry, Functional assay, Animal Model; UnconjugatedReactive species: Cynomolgus monkey, Human Isotype: Human IgG1Espèces hôtes: Human Conjugaison: UnconjugatedCas Number: 2566473-71-8Synonymes: Activin A receptor type I antibody | Activin A receptor type II like kinase 2 antibody | Activin receptor type I anti...
